SAFETY DATA SHEET

Date of issue/Date of revision

: 20 December 2023 Version



: 2

Europe

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier

Product name: STEELGUARD 801 WHITEProduct code: 00363918

Other means of identification

Not available.

1.2 Relevant identified uses of the substance or mixture and uses advised against		
Product use	: Professional applications, Used by spraying.	
Use of the substance/ mixture	: Coating.	
Uses advised against	: Product is not intended, labelled or packaged for consumer use.	

1.3 Details of the supplier of the safety data sheet

PPG Coatings Belgium BV/SRL Tweemontstraat 104 B-2100 Deurne Belgium Telephone +32-33606311 Fax +32-33606435

e-mail address of person responsible for this SDS

: Product.Stewardship.EMEA@ppg.com

sponsible for this 3D3

1.4 Emergency telephone number

Supplier

+31 20 4075210

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Product definition : Mixture
Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]
<mark>F∕</mark> am. Liq. 2, H225
Skin Irrit. 2, H315
Carc. 2, H351
Repr. 2, H361fd
STOT SE 3, H336
STOT RE 2, H373
The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.
See Section 16 for the full text of the U statements declared above

See Section 16 for the full text of the H statements declared above.

Code : 00363918	Date of issue/Date of revision	: 20 December 2023
STEELGUARD 801 WHITE		

SECTION 2: Hazards identification

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements Hazard pictograms

|--|--|--|

Signal word	: Danger
Hazard statements	 Fighly flammable liquid and vapour. Causes skin irritation. May cause drowsiness or dizziness. Suspected of causing cancer. Suspected of damaging fertility. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.

Precautionary statements

Prevention	:	Wear protective gloves, protective clothing and eye or face protection. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Do not breathe vapour.
Response	:	Get medical advice/attention if you feel unwell.
Storage	:	Store in a well-ventilated place. Keep container tightly closed.
Disposal	:	Dispose of contents and container in accordance with all local, regional, national and international regulations.
		P280, P210, P260, P314, P403 + P233, P501
Hazardous ingredients	÷	1,3,5-triazine-2,4,6-triamine
Supplemental label elements	:	Contains N,N'-ethane-1,2-diylbis(12-hydroxyoctadecan-1-amide). May produce an allergic reaction. Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles		Not applicable.
Special packaging requirem		
Containers to be fitted with child-resistant fastenings	:	Not applicable.
Tactile warning of danger	:	Not applicable.
2.3 Other hazards		
Product meets the criteria for PBT or vPvB	:	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do not result in classification	:	Prolonged or repeated contact may dry skin and cause irritation. Contains a substance that may emit formaldehyde if stored beyond its shelf life and/or during cure at curing temperatures greater than 60C/140F.

English (GB)	Europe	2/17
--------------	--------	------

Code : 00363918 STEELGUARD 801 WHITE Date of issue/Date of revision

: 20 December 2023

SECTION 3: Composition/information on ingredients

3.2 Mixtures	: Mixture				
Product/ingredient name	Identifiers	% by weight	Classification	Specific Conc. Limits, M-factors and ATEs	Туре
toluene	REACH #: 01-2119471310-51 EC: 203-625-9 CAS: 108-88-3 Index: 601-021-00-3	≥10 - ≤25	Flam. Liq. 2, H225 Skin Irrit. 2, H315 Repr. 2, H361d STOT SE 3, H336 STOT RE 2, H373 Asp. Tox. 1, H304	-	[1] [2]
1,3,5-triazine-2,4,6-triamine	REACH #: 01-2119485947-16 EC: 203-615-4 CAS: 108-78-1 Index: 613-345-00-2	≥5.0 - <10	Carc. 2, H351 Repr. 2, H361f STOT RE 2, H373 (urinary system)	-	[1] [3]
butanone	REACH #: 01-2119457290-43 EC: 201-159-0 CAS: 78-93-3 Index: 606-002-00-3	≥1.0 - ≤5.0	Flam. Liq. 2, H225 Eye Irrit. 2, H319 STOT SE 3, H336 EUH066	-	[1] [2]
N,N'-ethane-1,2-diylbis (12-hydroxyoctadecan- 1-amide)	REACH #: 01-2119978265-26 EC: 204-613-6 CAS: 123-26-2	≤0.30	Skin Sens. 1B, H317 Aquatic Chronic 3, H412	-	[1] [2]
			See Section 16 for the full text of the H statements declared above.		

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Туре

Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[3] Substance of equivalent concern

This mixture contains \geq 1% of titanium dioxide. The Annex VI classification of titanium dioxide does not apply to this mixture according to Note 10.

Occupational exposure limits, if available, are listed in Section 8.

SUB codes represent substances without registered CAS Numbers.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact: Remove contact lenses, irrigate copiously with clean, fresh water, holding the eyelids apart for at least 10 minutes and seek immediate medical advice.Inhalation: Remove to fresh air. Keep person warm and at rest. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel.Skin contact: Remove contaminated clothing and shoes. Wash skin thoroughly with soap and water or use recognised skin cleanser. Do NOT use solvents or thinners.	English (GB)	Europe	3/17
apart for at least 10 minutes and seek immediate medical advice.Inhalation: Remove to fresh air. Keep person warm and at rest. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained	Skin contact	0 0 0	oap and water
	Inhalation	irregular or if respiratory arrest occurs, provide artificial respiration or o	
	Eye contact		ng the eyelids

SECTION 4: First aid measures Ingestion : If swallowed, seek medical advice immediately and show the comperson warm and at rest. Do NOT induce vomiting. Protection of first-aiders : No action shall be taken involving any personal risk or without suisuspected that fumes are still present, the rescuer should wear a self-contained breathing apparatus. It may be dangerous to the pigive mouth-to-mouth resuscitation. 4.2 Most important symptoms and effects, both acute and delayed Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : Can cause central nervous system (CNS) depression. May cause dizziness. Skin contact : Can cause central nervous system (CNS) depression. Over-exposure signs/symptoms : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced foetal weight	tainer or label. Keep
Protection of first-aiders : No action shall be taken involving any personal risk or without suisuspected that fumes are still present, the rescuer should wear a self-contained breathing apparatus. It may be dangerous to the protection of first-aiders 4.2 Most important symptoms and effects, both acute and delayed Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : Can cause central nervous system (CNS) depression. May cause dizziness. Skin contact : Can cause central nervous system (CNS) depression. Ingestion : Can cause central nervous system (CNS) depression. Over-exposure signs/symptoms : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness	tainer or label. Keep
suspected that fumes are still present, the rescuer should wear a self-contained breathing apparatus. It may be dangerous to the p give mouth-to-mouth resuscitation. 4.2 Most important symptoms and effects, both acute and delayed Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : Can cause central nervous system (CNS) depression. May caus dizziness. Skin contact : Causes skin irritation. Defatting to the skin. Ingestion : Can cause central nervous system (CNS) depression. Over-exposure signs/symptoms Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness	
Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : Can cause central nervous system (CNS) depression. May caus dizziness. Skin contact : Causes skin irritation. Defatting to the skin. Ingestion : Can cause central nervous system (CNS) depression. Over-exposure signs/symptoms Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness	n appropriate mask or
Eye contact: No known significant effects or critical hazards.Inhalation: Can cause central nervous system (CNS) depression. May cause dizziness.Skin contact: Causes skin irritation. Defatting to the skin.Ingestion: Can cause central nervous system (CNS) depression.Over-exposure signs/symptomsEye contact: Adverse symptoms may include the following: pain or irritation watering rednessInhalation: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness	
Inhalation: Can cause central nervous system (CNS) depression. May cause dizziness.Skin contact: Causes skin irritation. Defatting to the skin.Ingestion: Can cause central nervous system (CNS) depression.Over-exposure signs/symptomsEye contact: Adverse symptoms may include the following: pain or irritation watering rednessInhalation: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness	
dizziness. Skin contact : Causes skin irritation. Defatting to the skin. Ingestion : Can cause central nervous system (CNS) depression. Over-exposure signs/symptoms Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness	
Ingestion : Can cause central nervous system (CNS) depression. Over-exposure signs/symptoms Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness	e drowsiness or
Over-exposure signs/symptoms Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness	
Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness	
pain or irritation watering redness Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness	
nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness	
increase in foetal deaths skeletal malformations	
Skin contact : Adverse symptoms may include the following: irritation redness dryness cracking reduced foetal weight increase in foetal deaths skeletal malformations skeletal malformations	
Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations	
4.3 Indication of any immediate medical attention and special treatment needed	
Notes to physician: In case of inhalation of decomposition products in a fire, sympton The exposed person may need to be kept under medical surveilla	
Specific treatments : No specific treatment.	ance for 46 hours.

Code :	00363918	Date of issue/Date of revision	: 20 December 2023
STEELGUARD	801 WHITE		

SECTION 5: Firefighting measures

5.1 Extinguishing media	
Suitable extinguishing media	: Use dry chemical, CO ₂ , water spray (fog) or foam.
Unsuitable extinguishing media	: Do not use water jet.
5.2 Special hazards arising f	rom the substance or mixture
Hazards from the substance or mixture	: Highly flammable liquid and vapour. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion.
Hazardous combustion products	: Decomposition products may include the following materials: carbon oxides nitrogen oxides phosphorus oxides halogenated compounds carbonyl halides metal oxide/oxides Formaldehyde.
5.3 Advice for firefighters	
Special precautions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures						
For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.				
For emergency responders	:	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".				
6.2 Environmental precautions	:	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).				
6.3 Methods and material for	6.3 Methods and material for containment and cleaning up					
Small spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.				

English (GB)	Europe	5/17
--------------	--------	------

Code : 00363918 STEELGUARD 801 WHITE	Date of issue/Date of revision : 20 December 2023
SECTION 6: Accide	ntal release measures
Large spill	: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product.
6.4 Reference to other sections	 See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment.

See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Avoid exposure - obtain special instructions before use. Avoid exposure during pregnancy. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not breathe vapour or mist. Do not ingest. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
7.2 Conditions for safe storage, including any incompatibilities	: Store between the following temperatures: 0 to 35°C (32 to 95°F). Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

See Section 1.2 for Identified uses.

Code	: 00363918	Date of issue/Date of revision	: 20 December 2023

STEELGUARD 801 WHITE

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

8.1 Control parameters

Occupational exposure limits

Product/ingredient name	Exposure limit values
1 0luene	EU OEL (Europe, 1/2022). Absorbed through skin.
	STEL: 384 mg/m ³ 15 minutes.
	STEL: 100 ppm 15 minutes.
	TWA: 192 mg/m ³ 8 hours.
	TWA: 50 ppm 8 hours.
butanone	EU OEL (Europe, 1/2022).
	STEL: 900 mg/m ³ 15 minutes.
	STEL: 300 ppm 15 minutes.
	TWA: 600 mg/m ³ 8 hours.
	TWA: 200 ppm 8 hours.
N,N'-ethane-1,2-diylbis(12-hydroxyoctadecan-	ACGIH TLV (United States).
1-amide)	TWA: 3 mg/m ³ Form: Respirable
	TWA: 10 mg/m³ Form: Total dust

Recommended monitoring procedures : Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs

Product/ingredient name	Туре	Exposure	Value	Population	Effects
toluene	DNEL	Long term Oral	8.13 mg/kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	56.5 mg/m ³	General population	Local
	DNEL	Long term Inhalation	56.5 mg/m ³	General population	Systemic
	DNEL	Long term Inhalation	192 mg/m ³	Workers	Local
	DNEL	Long term Inhalation	192 mg/m ³	Workers	Systemic
	DNEL	Long term Dermal	226 mg/kg bw/day	General population	Systemic
	DNEL	Short term Inhalation	226 mg/m ³	General population	
	DNEL	Short term Inhalation	226 mg/m ³	General population	Systemic
	DNEL	Long term Dermal	384 mg/kg bw/day	Workers	Systemic
	DNEL	Short term Inhalation	384 mg/m ³	Workers	Local
	DNEL	Short term Inhalation	384 mg/m ³	Workers	Systemic
1,3,5-triazine-2,4,6-triamine	DNEL	Long term Oral	0.42 mg/kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	1.5 mg/m ³	General population	
	DNEL	Long term Dermal	4.2 mg/kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	8.3 mg/m ³	Workers	Systemic
	DNEL	Long term Dermal	11.8 mg/kg bw/day	Workers	Systemic
	DNEL	Short term Inhalation	82.3 mg/m ³	Workers	Systemic
	DNEL	Short term Dermal	117 mg/kg bw/day	Workers	Systemic
butanone	DNEL	Long term Oral	31 mg/kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	106 mg/m ³	General population	Systemic
	DNEL	Long term Dermal	412 mg/kg bw/day	General population	
	DNEL	Short term Inhalation	450 mg/m ³	General population	•
	DNEL	Long term Inhalation	600 mg/m ³	Workers	Systemic
English (GB)	1	1	Europe	I	7/17

Code : 00363918 **STEELGUARD 801 WHITE** Date of issue/Date of revision

: 20 December 2023

SECTION 8: Exposure controls/personal protection

DNE	Short term Inhalation	900 mg/m³	Workers	Systemic
DNE	Long term Dermal	1161 mg/kg bw/day	Workers	Systemic

PNECs

Product/ingredient name	Туре	Compartment Detail	Value	Method Detail
toluene	-	Fresh water	0.68 mg/l	Sensitivity Distribution
	-	Marine water	0.68 mg/l	Sensitivity Distribution
	-	Sewage Treatment Plant	13.61 mg/l	Sensitivity Distribution
	-	Fresh water sediment	16.39 mg/kg dwt	Equilibrium Partitioning
	-	Marine water sediment	16.39 mg/kg dwt	-
butanone	-	Fresh water	55.8 mg/l	Sensitivity Distribution
	-	Marine water	55.8 mg/l	Sensitivity Distribution
	-	Sewage Treatment Plant	709 mg/l	Sensitivity Distribution
	-	Fresh water sediment	284.74 mg/kg dwt	Equilibrium Partitioning
	-	Marine water sediment	284.7 mg/kg dwt	Equilibrium Partitioning
	-	Soil	22.5 mg/kg dwt	Equilibrium Partitioning

8.2 Exposure controls Appropriate engineering : Use only with adequate ventilation. Use process enclosures, local exhaust ventilation controls or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment. Individual protection measures **Hygiene measures** : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that evewash stations and safety showers are close to the workstation location. Eye/face protection Chemical splash goggles. Use eye protection according to EN 166. Skin protection Hand protection : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated. When prolonged or frequently repeated contact may occur, a glove with a protection class of 6 (breakthrough time greater than 480 minutes according to EN 374) is recommended. When only brief contact is expected, a glove with a protection class of 2 or higher (breakthrough time greater than 30 minutes according to EN 374) is recommended. The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment. Gloves : For prolonged or repeated handling, use the following type of gloves:

Recommended: butyl rubber

Code : 00363918 STEELGUARD 801 WHITE	Date of issue/Date of revision	: 20 December 2023			
SECTION 8: Exposure controls/personal protection					

Body protection	: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti- static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.
Other skin protection	Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	: Respirator selection must be based on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator. If workers are exposed to concentrations above the exposure limit, they must use appropriate, certified respirators. Use a properly fitted, air-purifying or air-fed respirator complying with an approved standard if a risk assessment indicates this is necessary. Wear a respirator conforming to EN140. Filter type: organic vapour (Type A) and particulate filter P3
Environmental exposure controls	: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

<u>Appearance</u>							
Physical state	: 1	Liquid.					
Colour	: 1	White.					
Odour	: /	Aromatic.					
Odour threshold	: 1	Not available.					
Melting point/freezing point	i	May start to solidify at the following temperature: 103 to 115°C (217.4 to 239°F) This is based on data for the following ingredient: Paraffin waxes and Hydrocarbon waxes, chloro. Weighted average: -60.09°C (-76.2°F)					
Initial boiling point and boiling range	: :	>37.78°C					
Flammability	: 1	Not available.					
Upper/lower flammability or explosive limits	: (Greatest known range: Lower: 1.8% Upper: 11.5% (butanone)					
Flash point	: (Closed cup: 6°C					
Auto-ignition temperature	:						
	ſ	Ingredient name	°C	°F	Method		
	Ī	butanone	404	759.2			
Decomposition temperature	: :	Stable under recommend	led storage and	handling cond	itions (see Section 7).		
рН	: 1	Not applicable. insoluble	in water.				
Viscosity	: 1	Kinematic (40°C): >21 m	m²/s				
Viscosity	: :	> 100 s (ISO 6mm)					
Solubility(ies)	:						
Media		Result					
cold water		Not soluble					
English (GB)			Europe		9/17		

Code	: 00363918	Date of issue/Date of revision	: 20 December 2023
STEELGUAR	D 801 WHITE		

SECTION 9: Physical and chemical properties

2

Partition coefficient: n-octanol/ : Not applicable. water

Vapour pressure

			Vapoι	ır Press	sure at 20°C	Vap	our press	sure at 50°C
		Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method
		putanone	78.7564	10.5				
Evaporation rate	:	2 (toluene) compare	d with but	yl aceta	te			
Relative density	:	1.34						
Vapour density	:	Highest known value	e: 3.1 (Air	= 1) (to	oluene). Weig	hted ave	rage: 3.0	3 (Air = 1)
Explosive properties	:	The product itself is vapour or dust with a		,	the formation	of an ex	plosible n	nixture of
Oxidising properties	:	Product does not pre	esent an c	xidizing	hazard.			
Particle characteristics								
Median particle size	:	Not applicable.						
9.2 Other information								
No additional information.								

SECTION 10: Stability and reactivity

10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	: The product is stable.
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	: When exposed to high temperatures may produce hazardous decomposition products. Refer to protective measures listed in sections 7 and 8.
10.5 Incompatible materials	: Keep away from the following materials to prevent strong exothermic reactions: oxidising agents, strong alkalis, strong acids.
10.6 Hazardous decomposition products	: Depending on conditions, decomposition products may include the following materials: carbon oxides nitrogen oxides phosphorus oxides halogenated compounds Formaldehyde. carbonyl halides metal oxide/oxides

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008 Acute toxicity Code : 00363918 STEELGUARD 801 WHITE Date of issue/Date of revision

: 20 December 2023

SECTION 11: Toxicological information

Product/ingredient na	me	Re	sult	Species	Dose	Exposure
toluene		LC50 Inhalatio	on Vapour	Rat	49 g/m³	4 hours
		LD50 Dermal		Rabbit	8.39 g/kg	-
		LD50 Oral		Rat	5580 mg/kg	-
1,3,5-triazine-2,4,6-triamine		LC50 Inhalation	on Dusts and	Rat	>5190 mg/m ³	4 hours
		mists				
		LD50 Oral		Rat	3161 mg/kg	-
butanone		LD50 Dermal LD50 Oral		Rabbit Rat	6480 mg/kg 2737 mg/kg	-
N,N'-ethane-1,2-diylbis		LC50 Inhalatio	on Duete and	Rat	>5.11 mg/l	- 4 hours
(12-hydroxyoctadecan-1-amide)	mists	Dusis and	Mat	~5.11 mg/i	4 110015
	,	LD50 Dermal		Rat	>2000 mg/kg	_
		LD50 Oral		Rat	>2000 mg/kg	_
Conclusion/Summary :	There are r	no data availab	le on the mixtur	e itself.		
rritation/Corrosion						
Conclusion/Summary						
	Thoro oro n	o doto ovoilabl	e on the mixture	itaalf		
-						
Eyes :	: There are no data available on the mixture itself.					
Respiratory :	There are n	o data availabl	e on the mixture	e itself.		
<u>Sensitisation</u>						
Conclusion/Summary						
Skin :	There are r	no data availab	le on the mixtur	e itself.		
Respiratory :	There are r	no data availab	le on the mixtur	e itself.		
<u>Mutagenicity</u>						
Conclusion/Summary :	There are r	no data availab	le on the mixtur	e itself.		
Carcinogenicity						
	There are r	no data availab	le on the mixtur	e itself.		
Reproductive toxicity						
	There are r	no data availab	le on the mixtur	e itself.		
<u>Feratogenicity</u>						
	There are r	no data availah	le on the mixtur	e itself.		
Specific target organ toxicity						
get organ toxiony				Route of		

Product/ingredient name	Category	Route of exposure	Target organs	
toluene butanone	Category 3 Category 3		Narcotic effects Narcotic effects	

Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
₩uene	Category 2	-	-
1,3,5-triazine-2,4,6-triamine	Category 2		urinary system

Aspiration hazard

Product/ingredient name	Result
toluene	ASPIRATION HAZARD - Category 1

SECTION 11: Toxicological information Information on likely routes of exposure : Not available. Potential actue health effects : Can cause central nervous system (CNS) depression. May cause drowsiness or dizriness. Ingestion : Can cause central nervous system (CNS) depression. Skin contact : Can cause central nervous system (CNS) depression. Skin contact : Can cause central nervous system (CNS) depression. Skin contact : Can cause central nervous system (CNS) depression. Symotoms related to the physical. chemical and toxicological characteristics Inhelation : Adverse symptoms may include the following: nausea or vorniting headache drowsinessifatigue diziness/vertigo unconsciousness reduced foetal weight increase in foetal deaths skeletal matformations Ingestion : Adverse symptoms may include the following: increase in foetal deaths skeletal matformations Skin contact : Adverse symptoms may include the following: intration reduced foetal weight increases in foetal deaths skeletal matformations Eye contact : Adverse symptoms may include the following: intration reduces Delayad and immediate officits as well as chronic officits from short and long-term exposure Short term exposure Potential immediate Potential immediate : Not available. Condum exposure Potential immediate <	Code : 00363918 STEELGUARD 801 WHITE	Date of issue/Date of revision: 20 December 20	23
Information on likely : Not available. routes of exposure Potential acute health effects Inhalation : Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness. Ingestion : Can cause central nervous system (CNS) depression. Skin contact : Causes skin irritation. Defatting to the skin. Eye contact : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Inhalation : Adverse symptoms may include the following: nauses or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduces foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increases in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation reduced foetal weight increases in foetal deaths skeletal malformations Skort tom oxpoosure Potential deayed effects : Not available. effects Potential deayed effects : Not available. effects Potential deayed effects : Not available. effects Potential deayed effects : Not available. Long term exposure Potential deayed effects : Not available. Potential deayed effects : Not available. Pot		agical information	
routes of exposure Potential acute health offects Inhalation : Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness. Ingestion : Causes skin irritation. Defating to the skin. Eye contact : No known significant effects or critical hazards. Symptoms rolated to the physical, chemical and toxicological characteristics Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced foetal weight increase in foetal deaths skeletal maformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal maformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal maformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal maformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal maformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal maformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increases in foetal deaths skeletal maformations Eye contact : Adverse symptoms may include the following: pain or irritation watering reduced foetal weight increases swell as chronic effects from short and long-term exposure Short ferm exposure Potential inmediate effects as well as chronic effects from short and long-term exposure Short ferm exposure Potential inmediate effects : Not available. effects Potential inmediate is Not available. effects Potential inmediate is Not available. effects Potential inmediate is Not available. effects Not available. Conclusion/Summary : Not available. General : May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can			
Inhalation : Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness. Ingestion : Can cause central nervous system (CNS) depression. Skin contact : Causes skin irritation. Defatting to the skin. Eye contact : No known significant effects or critical hazards. Symptoms related to the physical. chemical and toxicological characteristics Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/ratgue dizziness/vertigo unconsciousness ir reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation redness dryness cracking reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation redness dryness cracking reduced foetal weight increase in foetal deaths skeletal malformations Eye contact : Adverse symptoms may include the following: pain or irritation watering reduced foetal weight increase in foetal deaths Skeletal malformations : Eye contact : Adverse symptoms may include the following: pain or irritation watering reduced foetal weight increase in foetal deaths : for target and immediate effects as well as chronic effects from short and long-term exposure Sho	routes of exposure		
dizziness. indiziness. Ingestion : Can cause central nervous system (CNS) depression. Skin contact : Causes skin intration. Defatting to the skin. Eye contact : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation redness cracking reduced foetal weight increase in foetal deaths skeletal malformations Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not availab	Potential acute health effect	<u>'S</u>	
Skin contact : Causes skin iritation. Defatting to the skin. Eye contact : No known significant effects or critical hazards. Symptoms related to the physical. chemical and toxicological characteristics Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: preduced foetal weight increase in foetal deaths skeletal malformations Eye contact : Adverse symptoms may include the following: pain or iritation watering reduces Delayed and immediate effects as well as chronic effects from short and long-term exposure Photential immediate effects : Not available. Long term exposure : Not available. Potential charpet effects : Not available. Potential charpet effects : Not available. Potential charpet effects : Not available. <	Inhalation		or
Eye contact : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Inhalation : Adverse symptoms may include the following: nausea or vomiling headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Eye contact : Adverse symptoms may include the following: pain or irritation watering reduced foetal weight increases Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure : Not available. Potential delayed effects : Not available. effects : Not available. Potential chronic health effects : Not available. Potential inmediate effects : Not available. Potential delayed effects : Not available.	Ingestion	: Can cause central nervous system (CNS) depression.	
Symptoms related to the physical, chemical and toxicological characteristics Inhalation : Adverse symptoms may include the following: nausea or vomiling headache drowsiness/fatigue dizzinessi/vertigo unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduces foetal weight increase in foetal deaths skeletal malformations Eye contact : Adverse symptoms may include the following: pain or irritation reduces symptoms may include the following: pain or irritation watering reduces symptoms may include the following: pain or irritation watering reduces in the following: pain or irritation watering reduces symptoms may include the following: pain or irritation watering reduces symptoms may include the following: pain or irritation reduces symptoms reduces symptoms pain or irritation reduces symptoms reduces symptoms reduces data	Skin contact	: Causes skin irritation. Defatting to the skin.	
Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduced foetal weight increase in foetal deaths skeletal malformations Eye contact : Adverse symptoms may include the following: irritation reduced foetal weight increase in foetal deaths skeletal malformations Eye contact : Adverse symptoms may include the following: pain or irritation watering reduces as well as chronic effects from short and long-term exposure Short term exposure Potential immediate effects : Not available. Potential delayed effects : Not available. Long term exposure : Not available. Potential delayed effects : Not available. Potential delayeed effects <td< td=""><td>Eye contact</td><td>: No known significant effects or critical hazards.</td><td></td></td<>	Eye contact	: No known significant effects or critical hazards.	
nausea of vomiting or headache drowsiness/fatigue dizziness/ertigo unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduced foetal weight increase in foetal deaths skeletal malformations skeletal malformations Eye contact : Adverse symptoms may include the following: pain or irritation redness dyness cracking reduced foetal weight increases Delayed and immediate offects as well as chronic offects from short and long-term exposure Potential immediate : Not available. Long term exposure : Not available. </td <td>Symptoms related to the phy</td> <td>ysical, chemical and toxicological characteristics</td> <td></td>	Symptoms related to the phy	ysical, chemical and toxicological characteristics	
reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: irritation reduceds dryness cracking reduced foetal weight increase in foetal deaths skeletal malformations Eye contact : Adverse symptoms may include the following: pain or irritation watering reduceds Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Potential delayed effects : Not available. Conclusion/Summary : Not available. General : May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Carcinogenicity	Inhalation	nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness reduced foetal weight increase in foetal deaths	
irritation redness dryness cracking reduced foetal weight increase in foetal deaths skeletal malformations skeletal malformations Eye contact : Adverse symptoms may include the following: pain or irritation watering reduced foetal weight increase in foetal deaths Skeletal malformations skeletal malformations Eye contact : Adverse symptoms may include the following: pain or irritation watering reducess Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate Potential immediate : Not available. effects Potential delayed effects Potential delayed effects : Not available. effects Potential delayed effects Potential delayed effects : Not available. Potential chronic health effects Not available. Potential chronic health effects Not available. Conclusion/Summary : Not available. General : May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/o	Ingestion	reduced foetal weight increase in foetal deaths	
pain or irritation watering redness Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Long term exposure : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary : Not available. General : May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Carcinogenicity : Suspected of causing cancer. Risk of cancer depends on duration and level of	Skin contact	irritation redness dryness cracking reduced foetal weight increase in foetal deaths	
Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. Potential immediate : Not available. . Potential delayed effects : Not available. . Potential delayed effects : Not available. . Potential delayed effects : Not available. . Potential chronic health effects . . Not available. . . Conclusion/Summary : Not available. . General : May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Carcinogenicity : Suspected of causing cancer. Risk of cancer depends on duration and level of	Eye contact	pain or irritation watering	
Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure . Potential immediate : Not available. effects Potential delayed effects : Not available. Potential delayed effects : Not available. . Potential delayed effects : Not available. . Potential chronic health effects . . Not available. . . Conclusion/Summary : Not available. . General : May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Carcinogenicity : Suspected of causing cancer. Risk of cancer depends on duration and level of	Delayed and immediate effe	<u>cts as well as chronic effects from short and long-term exposure</u>	
effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary : Not available. General : May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Carcinogenicity : Suspected of causing cancer. Risk of cancer depends on duration and level of			
Long term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Not available. : Not available. Conclusion/Summary : Not available. General : May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Carcinogenicity : Suspected of causing cancer. Risk of cancer depends on duration and level of		: Not available.	
Potential immediate effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary : Not available. General : May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Carcinogenicity : Suspected of causing cancer. Risk of cancer depends on duration and level of	Potential delayed effects	: Not available.	
effects Potential delayed effects : Not available. Potential chronic health effects Not available. Conclusion/Summary : Not available. General : May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Carcinogenicity : Suspected of causing cancer. Risk of cancer depends on duration and level of			
Potential chronic health effects Not available. Conclusion/Summary : Not available. General : May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Carcinogenicity : Suspected of causing cancer. Risk of cancer depends on duration and level of		: Not available.	
Not available. Conclusion/Summary : Not available. General : May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Carcinogenicity : Suspected of causing cancer. Risk of cancer depends on duration and level of	Potential delayed effects	: Not available.	
Conclusion/Summary : Not available. General : May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Carcinogenicity : Suspected of causing cancer. Risk of cancer depends on duration and level of	Potential chronic health effe	ects	
General: May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis.Carcinogenicity: Suspected of causing cancer. Risk of cancer depends on duration and level of	Not available.		
General: May cause damage to organs through prolonged or repeated exposure. Prolonged repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis.Carcinogenicity: Suspected of causing cancer. Risk of cancer depends on duration and level of	Conclusion/Summarv	: Not available.	
Carcinogenicity : Suspected of causing cancer. Risk of cancer depends on duration and level of		: May cause damage to organs through prolonged or repeated exposure. Prolon	
	Carcinogenicity		
English (GB) Europe 12/1	English (CP)	Europa	12/17

Code : 00363918	Date of issue/Date of revision	: 20 December 2023
STEELGUARD 801 WHITE		

SECTION 11: Toxicological information

Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: Suspected of damaging fertility. Suspected of damaging the unborn child.

: Not available.

Other information

Prolonged or repeated contact may dry skin and cause irritation. Repeated exposure to high vapor concentrations may cause irritation of the respiratory system and permanent brain and nervous system damage. Inhalation of vapour/aerosol concentrations above the recommended exposure limits causes headaches, drowsiness and nausea and may lead to unconsciousness or death. Contains a substance that may emit formaldehyde if stored beyond its shelf life and/or during cure at curing temperatures greater than 60C/140F. Avoid contact with skin and clothing.

11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Not available.

11.2.2 Other information

Not available.

SECTION 12: Ecological information

12.1 Toxicity

Product/ingredient name	Result	Species	Exposure
7,3,5-triazine-2,4,6-triamine	Acute EC50 200 mg/l	Daphnia	48 hours
N,N'-ethane-1,2-diylbis(12-hydroxyoctadecan- 1-amide)	Acute EC50 29 to 43 mg/l	Algae - Pseudokirchneriella subcapitata	72 hours
	Acute EC50 94 mg/l	Daphnia - Daphnia magna	48 hours

Conclusion/Summary : There are no data available on the mixture itself.

12.2 Persistence and degradability

Product/ingredient name	Test	Result	Dose	Inoculum
N,N'-ethane-1,2-diylbis (12-hydroxyoctadecan- 1-amide)	-	63 % - 28 days	-	-
Conclusion/Summary	: There are	no data available on the mixtur	e itself.	

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
toluene N,N'-ethane-1,2-diylbis(12-hydroxyoctadecan- 1-amide)	-	-	Readily Readily

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
Koluene 1,3,5-triazine-2,4,6-triamine butanone N,N'-ethane-1,2-diylbis(12-hydroxyoctadecan- 1-amide)	2.73 -1.22 0.3 >6	8.32 3.8 - -	Low Low Low High

12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

English (GB) Europe 13/17

Code : 003	363918	Date of issue/Date of revision	: 20 December 2023
STEELGUARD 80 ⁴	1 WHITE		

SECTION 12: Ecological information

Mobility

: Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Endocrine disrupting properties

Not available.

12.7 Other adverse effects

No known significant effects or critical hazards.

SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

Product

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste : Yes.

European waste catalogue (EWC)

Waste code	Waste designation	
08 01 11*	waste paint and varnish containing organic solvents or other hazardous substances	
Packaging	+	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.	
Type of packaging	European waste catalogue (EWC)	
Container	15 01 06 mixed packaging	
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.	

Code	: 00363918	Date of issue/Date of revision	: 20 December 2023
STEELGUAR	RD 801 WHITE		

14. Transport information

	ADR/RID	ADN	IMDG	ΙΑΤΑ
14.1 UN number or ID number	UN1263	UN1263	UN1263	UN1263
14.2 UN proper shipping name	PAINT	PAINT	PAINT	PAINT
14.3 Transport hazard class(es)	3	3	3	3
14.4 Packing group	Π	Ш	II	II
14.5 Environmental hazards	No.	No.	No.	No.
Marine pollutant substances	Not applicable.	Not applicable.	Not applicable.	Not applicable.

Additional information

ADR/RID Tunnel code ADN IMDG	None identified. (D/E) None identified. None identified.	
ΙΑΤΑ	The environmentally hazardous substance mark may appear if required by other transportation regulations.	
14.6 Special preuser	ions for : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.	
14.7 Maritime tra bulk according t	••	

instruments

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture <u>EU Regulation (EC) No. 1907/2006 (REACH)</u>

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

Intrinsic property	Ingredient name	Status	Reference number	Date of revision
Substance of equivalent concern for human health	melamine	Candidate	D(2022) 9120-DC	1/17/2023
Substance of equivalent concern for environment	melamine	Candidate	D(2022) 9120-DC	1/17/2023

Code : 00363918 Date of issue/Date of revi	ision : 20 December 2023
STEELGUARD 801 WHITE	

SECTION 15: Regulatory information

Annex XVII - Restrictions : Not applicable. on the manufacture, placing on the market

and use of certain dangerous substances, mixtures and articles

Explosive precursors : Not applicable.

Ozone depleting substances (1005/2009/EU)

Not listed.

Seveso Directive

This product is controlled under the Seveso Directive.

<u>Danger criteria</u>

Category

P5c

15.2 Chemical safety assessment

: No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms

ATE = Acute Toxicity Estimate

CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]

DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

PNEC = Predicted No Effect Concentration

RRN = REACH Registration Number

PBT = Persistent, Bioaccumulative and Toxic

vPvB = Very Persistent and Very Bioaccumulative

ADR = The European Agreement concerning the International Carriage of Dangerous Goods by Road

ADN = European Provisions concerning the International Carriage of Dangerous Goods by Inland Waterway

IMDG = International Maritime Dangerous Goods

IATA = International Air Transport Association

Full text of abbreviated H statements

H 225	Highly flammable liquid and vapour.
H304	May be fatal if swallowed and enters airways.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H336	May cause drowsiness or dizziness.
H351	Suspected of causing cancer.
H361d	Suspected of damaging the unborn child.
H361f	Suspected of damaging fertility.
H361fd	Suspected of damaging fertility. Suspected of damaging the unborn child.
H373	May cause damage to organs through prolonged or repeated exposure.
H412	Harmful to aquatic life with long lasting effects.
EUH066	Repeated exposure may cause skin dryness or cracking.

Full text of classifications [CLP/GHS]

English (GB)	Europe	16/17

ERM (CHRONIC) AQUATIC HAZARD - Category 3
ERM (CHRONIC) AQUATIC HAZARD - Category 3
TION HAZARD - Category 1 OGENICITY - Category 2 S EYE DAMAGE/EYE IRRITATION - Category 2 ABLE LIQUIDS - Category 2 DUCTIVE TOXICITY - Category 2 ORROSION/IRRITATION - Category 2 NSITISATION - Category 1B C TARGET ORGAN TOXICITY - REPEATED EXPOSURE - 2 C TARGET ORGAN TOXICITY - SINGLE EXPOSURE - 3

Date of previous issue	1	29 August 2022
Prepared by	:	EHS
Version	1	2

<u>Disclaimer</u>

The information contained in this data sheet is based on present scientific and technical knowledge. The purpose of this information is to draw attention to the health and safety aspects concerning the products supplied by us, and to recommend precautionary measures for the storage and handling of the products. No warranty or guarantee is given in respect of the properties of the products. No liability can be accepted for any failure to observe the precautionary measures described in this data sheet or for any misuse of the products.